Clinical OMICS

SEP-OCT 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1023557

Contents of this Issue

Navigation

Page 31 of 51

30 Clinical OMICs September/October 2018 www.clinicalomics.com Keeping the Beat Researchers Find New Genetic Variants Linked to Atrial Fibrillation, Suggesting New Treatment Targets By Sophia Ktori A n international research effort headed by a team at the University of Michigan (UM) has linked more than 140 genetic variants and 150 protein-coding genes with an increased risk for developing atrial fibrillation (AF), a heart rhythm disorder that affects an estimated 2.7 to 6.1 mil- lion people in the United States and more than 30 million world-wide. The scientists carried out a genome-wide association study (GWAS) that analyzed genetic data from more than 1 million people, including patients with AF and healthy controls, to find which variants might play a contributing role. They hope that the findings will offer up new genetic insights into the biological processes that cause AF, which could support screening tests, and potential new targets for drug discovery and development. As a result of their work, the researchers have used the new data to build a statistical tool that can predict an indi- vidual's risk for developing the disorder based on which of the genetic variants are present. "This polygenic risk score could be used in a clinical setting to help identify high-risk individuals, so that preventive measures can be taken before they develop AF, which can have fatal consequences," com- mented research co-lead Cristen Willer, Ph.D., associate pro- fessor at UM Department of Internal Medicine, and head of the university's Willer lab. The GWAS data might help to increase our understanding of why and how AF is triggered and maintained, so that genetic screening of patients who already have AF could help clinicians decide on the best course of therapy. The protein-coding genes and regulatory sequences iden- tified could also represent targets both for developing new treatments for AF, and for repurposing existing medicines that are used to treat unrelated disorders. "Each one of the genetic variants and genes that we have identified rep- resents a clue to the underlying pathways and processes that cause AF," said Willer in an interview with Clinical OMICs. "Further research will be needed to identify which could feasibly be used to develop new drugs for treating or preventing the disorder." The UM team and colleagues in the U.S., Japan, and Scan- dinavia report their studies in Nature Genetics, in a paper entitled, "Biobank-driven genomic discovery yields new insight into atrial fibrillation biology." Potentially Thousands of AF-Related Variants Although AF is more prevalent in older people, the disor- der still affects an estimated 2% of people under-65. And as Wavebreakmedia Ltd / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - SEP-OCT 2018